Last reviewed · How we verify
Modified bismuth-containing eradication treatment
Bismuth-containing compounds eradicate Helicobacter pylori by disrupting bacterial cell wall integrity and inhibiting urease enzyme activity.
A bismuth-based combination therapy that eradicates Helicobacter pylori infection through multiple antimicrobial mechanisms. Used for Helicobacter pylori infection eradication.
At a glance
| Generic name | Modified bismuth-containing eradication treatment |
|---|---|
| Sponsor | Athens Medical Center |
| Drug class | Antimicrobial combination therapy |
| Target | Helicobacter pylori cell wall and urease enzyme |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Bismuth salts accumulate in H. pylori cells and damage the bacterial cell wall and membrane, while also inhibiting the urease enzyme that the bacterium uses to survive in acidic gastric environments. This combination of direct bactericidal activity and enzyme inhibition makes bismuth an effective component of multi-drug eradication regimens for H. pylori infection.
Approved indications
- Helicobacter pylori infection eradication as part of combination therapy
Common side effects
- Nausea
- Abdominal discomfort
- Diarrhea
- Darkening of stool
- Metallic taste
Key clinical trials
- Clinical Evaluation of a 14day Modified Bismuth Quadruple Therapy for the Eradication of Helicobacter Pylori in a High Clarithromycin and Metronidazole Resistance Area Regarding Patients With Peptic Ulcer and Non Ulcer Dyspepsia (PHASE4)
- Helicobacter Pylori Eradication Rates of Bismuth-containing Quadruple Therapy vs Modified Quadruple Therapy in Korea (PHASE4)
- Pilot Study of a 14-day Modified Sequential Therapy for Helicobacter Pylori Infection (PHASE4)
- A Pilot Study of a 14-day Modified Sequential Therapy for Helicobacter Pylori Infection (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: